.png)
Healthspan Capital is a venture capital firm with a mission to broadly invest and support longevity biotechnology ('LongBio') companies developing therapeutics to extend healthy human lifespan.
Key people at Healthspan Capital.
Key people at Healthspan Capital.
Healthspan Capital is a venture capital firm specializing in early-stage investments in longevity biotechnology ("LongBio"), focusing on companies developing therapeutics to extend healthy human lifespan by targeting the fundamental biological drivers of aging. Their mission is to significantly extend human lifespan by supporting innovations in DNA repair, regenerative medicine, and other cutting-edge longevity science. Healthspan Capital invests primarily in pre-seed to Series A biotech startups, aiming to revolutionize healthcare by addressing aging as a root cause of disease[1][2][4].
Founded in 2021 by Sebastian Brunemeier, Nathan Cheng, and Michael Chinen, Healthspan Capital emerged as one of the first publicly accessible longevity-focused venture funds, structured as a rolling fund on AngelList. Sebastian Brunemeier, a biotech entrepreneur with a background in aging research and company creation, leads the firm. His experience includes founding multiple biotech startups and working at Apollo Health Ventures, the first large longevity biotech venture fund. The firm’s founding reflects a convergence of deep scientific expertise and investment acumen aimed at accelerating the development of rejuvenation biotechnologies[2][4].
Healthspan Capital rides the wave of increasing capital inflow and innovation in longevity biotech, a sector that saw over $3 billion invested in 2021 and includes more than 140 companies with a combined market capitalization exceeding $30 billion. The firm’s focus on therapeutics that target aging aligns with a broader trend toward treating aging as a modifiable condition rather than an inevitable decline, which could transform medicine and healthcare economics. Their investments support the growing ecosystem of longevity startups, helping to accelerate scientific breakthroughs and commercial viability in this emerging field[4].
Looking ahead, Healthspan Capital is poised to deepen its influence as longevity biotech matures, potentially expanding its portfolio into more diverse therapeutic modalities and later-stage investments. Trends such as advances in regenerative medicine, AI-driven drug discovery, and personalized therapies will likely shape their investment strategy. As public and private interest in extending healthspan grows, Healthspan Capital’s role as a specialized, mission-driven investor will become increasingly critical in bridging early scientific innovation and market impact, helping to redefine human health and lifespan[1][4].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2025 | Oisin Biotechnologies | $10.0M Series A | — | 305 Ventures, Rebel Fund, Zachary Rapp |
| Dec 1, 2022 | Jung+ Longevity | $570K Seed | — | — |
| Aug 1, 2018 | CB Therapeutics | $120K Seed | — | 305 Ventures, Rebel Fund, Zachary Rapp |
